Stay updated on CPX-351 and Quizartinib in AML Clinical Trial

Sign up to get notified when there's something new on the CPX-351 and Quizartinib in AML Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the CPX-351 and Quizartinib in AML Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 6 to 7, indicating a recent update in the context of Medical and healthcare-related publications and documentation.
    Difference
    0.3%
    Check dated 2024-05-22T07:52:23.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    15 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 2023-11-30 to 2024-05-08, indicating an update in the information related to the Medical and healthcare-related publications and documentation for the study on Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome.
    Difference
    1.0%
    Check dated 2024-05-09T01:48:35.000Z thumbnail image
  7. Check
    23 days ago
    Change Detected
    Difference
    3%
    Check dated 2024-04-30T22:21:44.000Z thumbnail image

Stay in the know with updates to CPX-351 and Quizartinib in AML Clinical Trial

Enter your email address, and we'll notify you when there's something new on the CPX-351 and Quizartinib in AML Clinical Trial page.